Covid-19 vaccine in Australia 'likely' in 2021


Morrison said CSL is expected to deliver 3.8 million doses of the AstraZeneca vaccine, which is now undergoing late-stage clinical trials in Britain, Brazil and South Africa, in January and February next year.

'Australians will gain free access to a COVID-19 vaccine in 2021 if trials prove successful, ' Mr Morrison said. A massive distribution of the vaccine was evidently planned to show that the administration was acting on the COVID-19 pandemic which has infected and killed more Americans than any other nation in the world.

As a result, the further recruitment of the candidates for the trials has been put on hold. Now in Phase 1, animal testing has been positive and widespread clinical trials are expected later this year. Besides the acquisition of the CSL drug, the country meant to receive an agreement of intent from the company to manufacture it.

Meanwhile, the country' vaccine expert panel has sought clarifications regarding the documents submitted by developers of Russia's coronavirus vaccine Sputnik V. The documents shared with the Philippine government contain the findings of Phase 1 and 2 of the clinical trials of Sputnik V. Officials are awaiting the response of manufacturer Gamaleya research institute, Vergeire added.

J&J's vaccine is one of over a hundred worldwide being developed in response to the coronavirus pandemic, which has infected almost 26.5 million people and led to some 869,323 deaths.

A coronavirus vaccine set to be rolled out in Australia in January will require two injections and is expected to provide immunity for several years, health minister Greg Hunt said today. Nature Medicine. Published online September 3, 2020. doi:10.1038/s41591-020-1070-6. The market capitalisation of CSL stood at A$126.9 billion with almost 454.77 million shares trading on the ASX. Here is a good news about the indigenous "Covaxin" developed by Bharat Biotech. CSL operates in three businesses- CSL Behring, CSL Plasma & Seqirus.

The University of Queensland is now undertaking a Phase 1 clinical study on UQCSL V451 to assess safety and immunogenicity in healthy volunteers.

In a Skype interview with CNN, Richard Horton, editor-in-chief of The Lancet, said there will not be a vaccine available for public use by the end of October and President Trump is simply wrong about that.

Premier League ends deal with Chinese broadcast partner
The Premier League is set to bow to pressure and agree to televise all top-flight fixtures while matches are played behind closed doors.

About 28 manufacturers have shared their annual production plans for COVID-19 vaccines - through 2023 - with UNICEF, which said in a market assessment that the drug makers were willing to collectively produce "unprecedented quantities" of vaccines over the coming 1-2 years.

Similarly, the University of Queensland vaccine is showing promising results.

Its trials globally will include 60,000 volunteers. With this agreement, Australia is set to receive the first batch of AZD1222 in early 2021.

AstraZeneca would distribute 33.8mln doses and CSL 51mln, in deals worth £900mln together.

Australia had declared in August that it meant to purchase AZD1222, alongside an arrangement of goal from CSL to make it.

Meanwhile, the Russian Health Ministry registered the first vaccine against COVID-19, named Sputnik V, on August 11. We will see what happens with vaccines that are apparently being rushed, such as the ones in Russian Federation and the U.S., but we must wait for those that will meet the established requirements of the World Health Organization.

Moreover, funds will be used for the acquisition of equipment, recruitment, training & redeployment of personnel as well as retooling & reconfiguration of already existing manufacturing facilities.

Prime Minister Scott Morrison is expected to announce the government's agreements for the supply of both vaccine candidates with the respective companies later Monday.